D
David R. Spriggs
Researcher at Harvard University
Publications - 200
Citations - 7818
David R. Spriggs is an academic researcher from Harvard University. The author has contributed to research in topics: Ovarian cancer & Chemotherapy. The author has an hindex of 53, co-authored 199 publications receiving 7260 citations. Previous affiliations of David R. Spriggs include Kettering University & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
Robert A. Soslow,Guangming Han,Kay J. Park,Karuna Garg,Narciso Olvera,David R. Spriggs,Noah D. Kauff,Douglas A. Levine +7 more
TL;DR: Preliminary data indicate potential strong associations between morphology and genotype in high-grade serous carcinomas in BRCA1-associated and unassociated cases.
Journal ArticleDOI
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Rachel N. Grisham,Gopa Iyer,Karuna Garg,Deborah DeLair,David M. Hyman,Qin Zhou,Alexia Iasonos,Michael F. Berger,Fanny Dao,David R. Spriggs,Douglas A. Levine,Carol Aghajanian,David B. Solit +12 more
TL;DR: This study sought to determine whether BRAF or KRAS mutation status was associated with disease stage and/or histology in patients with SB and LGS ovarian cancer.
Journal ArticleDOI
Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma
Yanxia Zhao,Jinghong Cao,Alexander Melamed,Michael J. Worley,Allison Gockley,Dennis Jones,Hadi Tavakoli Nia,Yanling Zhang,Triantafyllos Stylianopoulos,Ashwin S. Kumar,Ashwin S. Kumar,Fotios Mpekris,Meenal Datta,Yao Sun,Limeng Wu,Xing Gao,Oladapo Yeku,Marcela G. del Carmen,David R. Spriggs,Rakesh K. Jain,Lei Xu +20 more
TL;DR: It is reported that targeting angiotensin signaling with losartan can reduce extracellular matrix in ovarian tumors and the associated physical barriers that normally hinder drug delivery and efficacy, leading to better anticancer therapeutic effect.
Journal ArticleDOI
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies
TL;DR: It is shown that CRM-based methods are an improvement over the SM in terms of accuracy and optimal dose allocation in almost all cases, except when the true dose is among the lower levels.
Journal ArticleDOI
Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
Andrew D. Seidman,Daniel Hochhauser,Marc J. Gollub,Bonnie Edelman,Tzy-Jyun Yao,Clifford A. Hudis,Prudence A. Francis,David Fennelly,Theresa Gilewski,Mary Ellen Moynahan,Violante Currie,José Baselga,William P. Tong,Mary O'Donaghue,Rori Salvaggio,Lucienne Auguste,David R. Spriggs,Larry Norton +17 more
TL;DR: Paclitaxel demonstrates activity against metastatic breast cancer when administered over 96 hours to patients with disease that recently had progressed during short taxane exposure, and supports preclinical data that suggest variability in efficacy and resistance patterns to pac litaxel based on duration of exposure.